NASDAQ · Biotechnology

SRRK (SRRK) Stock

$45.85 -3.06% NASDAQ: SRRK Healthcare

Valuation

MetricValue
Price$45.85
Market Cap$5.49B
P/E Ratio-19.24
P/B Ratio19.68
P/S Ratio0.00
EPS (TTM)$-3.29
52-Week High$57.94
52-Week Low$27.07
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-138.94%
ROA-54.30%
ROCE-157.14%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.75
Current Ratio7.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$19.0M$33.0M$0$0$0
Operating Profit$-130.0M$-134.0M$-171.0M$-252.0M$-385.0M
Net Profit$-132.0M$-135.0M$-166.0M$-246.0M$-378.0M
EPS$-3.59$-2.21$-1.99$-2.47$-3.29
Op Margin-690.5%-404.8%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$304.0M$358.0M$311.0M$475.0M$404.0M
Total Liabilities$132.0M$98.0M$86.0M$106.0M$159.0M
Cash$213.0M$103.0M$102.0M$178.0M$324.0M
Borrowings$84.0M$69.0M$62.0M$65.0M$109.0M

Latest News

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA) Business Wire · Jul 20, 2026 Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker BioPharma Dive · Jul 20, 2026 Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 17, 2026 Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026 Business Wire · Jul 16, 2026 Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD Business Wire · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-127.0M$-133.0M$-145.0M$-201.0M$-300.0M
Investing Cash Flow$129.0M$-173.0M$41.0M$-76.0M$218.0M
Financing Cash Flow$7.0M$0$5.0M$29.0M$0
Net Cash Flow$52.0M$-110.0M$-2.0M$76.0M$147.0M
Free Cash Flow$-132.0M$-134.0M$-145.0M$-201.0M$-301.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-12.30
FCF Yield-5.57%
Quick Ratio8.64
Interest Coverage-55.00
Return 1Y23.74%
Return 3Y622.73%
Return 5Y53.95%

Ownership

Insiders Held0.78%
Institutions Held117.18%
Institutions Float Held118.10%
Institutional HolderSharesReport Date
FMR, LLC17,243,1522026-03-31
Siren, L.L.C.10,825,0132026-03-31
Redmile Group, LLC9,066,6212026-03-31
Blackrock Inc.7,469,2932026-03-31
Samsara BioCapital, LLC6,897,6522026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADPT $24.93 +5.64% -69.84 $3.99B 0.00%
BEAM $25.62 +2.19% -35.36 $2.64B 0.00%
CDTXCidara Therapeutics, Inc. $221.38 +0.00% -25.99 $5.61B 0.00%
IDYA $36.02 -2.05% -22.12 $3.42B 0.00%
IRON $73.86 -1.01% -9.08 $2.82B 0.00%

About SRRK

SRRK stock trades at $45.85 with a market capitalization of $5.49B. The stock is valued at a price-to-earnings (P/E) ratio of -19.24, price-to-book of 19.68, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $27.07 and $57.94, and currently trades 20.9% below its 52-week high.

On profitability, SRRK generates a return on equity (ROE) of -138.94%, return on capital employed of -157.14%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides